产品
编 号：F761726
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 946415-64-1
产品详情
生物活性：
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.
体内研究：
Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2?/? skin grafted onto the humanized mice.Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems.Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice.Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:15 μg
Administration:Oral administration; daily, for 5 days and weekly dosing
Result:Showed robust protection against graft rejection and prolongs graft survival.Reduced proliferation of CD8+ T cells and reduced release of TNF.Increased the concentration of IL-10.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.)
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Had tolerant to autologous skin grafts in humanized mice.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:0, 5, 10, and 15 μg
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Increased human Ig on the surface of CD4+ and CD8+ T cells.Had free mAb in the serum of mice
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.
体内研究：
Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2?/? skin grafted onto the humanized mice.Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems.Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice.Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:15 μg
Administration:Oral administration; daily, for 5 days and weekly dosing
Result:Showed robust protection against graft rejection and prolongs graft survival.Reduced proliferation of CD8+ T cells and reduced release of TNF.Increased the concentration of IL-10.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.)
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Had tolerant to autologous skin grafts in humanized mice.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth)
Dosage:0, 5, 10, and 15 μg
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Increased human Ig on the surface of CD4+ and CD8+ T cells.Had free mAb in the serum of mice
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备